Pomdoctor Ltd. POM
What this company does
Written from the business description in POMDOCTOR LIMITED's annual report to the U.S. Securities and Exchange Commission, filed 14 May 2026. Every sentence was checked against that document before publication.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
No chart to show — the reason differs by year; see each year in the table below.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue CNY B | 0.4 | 0.3 | 0.3 |
| Operating income CNY B | −0.1 | −0.0 | −0.0 |
| EBITDA CNY B | −0.1 | −0.0 | −0.0 |
| Income tax CNY B | 0.0 | · | · |
| Net income CNY B | −0.1 | −0.0 | −0.0 |
| Free cash flow CNY B | −0.1 | −0.0 | −0.0 |
| EPS, diluted CNY | −21.96 | −22.72 | −23.04 |
| Dividend / sh CNY | · | · | · |
| Payout % | · | · | · |
| ROE % | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
This company against its peers
Reconciled in 3 of 19 fiscal years. 82 checks could not be computed.